Objective
To evaluate the cost effectiveness of human papillomavirus vaccine (HPV) for treating cervical cancer.
Methods
We constructed a Markov model to evaluate the cost-effectiveness of HPV versus Chinese healthy women aged 18 to 25 for treating Cervical Cancer. We calculated the clinical benefits and cost-effectiveness and judged the results based on willing to pay. Sensitivity analysis was made for parameters like cost, discounting rate and vaccine efficacy.
Results
HPV vaccination was a cost-effective option under the local willing to pay value with the incremental cost utility ratio 43 489 per QALY gained. It proved that vaccination was an economic and effective solution.
Conclusion
Given the results of Markov model, the cost effectiveness of HPV vaccination of Chinese women aged 18 to 25 is positive. Considering the data sources and model hypothesis, this report has some limitations. Further studies are warranted.
Citation：
SUN Yuxin, LIU Yongjun, LIU Tong. Economic evaluation of human papillomavirus vaccine versus Chinese women aged 18 to 25 for treating cervical cancer. Chinese Journal of Evidence-Based Medicine, 2017, 17(1): 102-107. doi: 10.7507/1672-2531.201610004
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
Cutts FT, Franceschi S, Goldie S,et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ, 2007, 85(9): 719-726.
|
| 2. |
Lu W, Duan X, Cen Y. Overview in Epidemiology on Cervical Cancer. Inner Mongolia Med, 2007, 39(8): 967-970.
|
| 3. |
Sanjose SD, Quint WG, Alemany L,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11(11): 1048-1056.
|
| 4. |
Zhu FC, Chen W, Hu YM,et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer, 2014, 135(11): 2612-2622.
|
| 5. |
人乳头瘤病毒预防性疫苗临床试验有效性评估专家组. 有关人乳头瘤病毒预防性疫苗临床试验有效性评估的专家共识. 中华肿瘤杂志, 2013, 35(7): 552-554.
|
| 6. |
Levin CE, Sellors J, Shi JF,et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 2010, 127(6): 1404-1411.
|
| 7. |
唐晓, 乔友林, 李国荣, 等. Markov 模型在DALY 计算中的应用. 中国卫生统计, 2012, 29(2): 296-298.
|
| 8. |
Simonella L, Howard K, Canfell K. A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes, 2014, 7(1): 899.
|
| 9. |
慈璞娲, 赵方辉, 王临虹, 等. 宫颈上皮内瘤变自然史转移概率的研究. 中国肿瘤, 2011, 20(9): 694-698.
|
| 10. |
陈蕊. 利用 Markov 模型对宫颈癌筛查方案的卫生经济学评价研究与应用. 华南理工大学, 2015.
|
- 1. Cutts FT, Franceschi S, Goldie S,et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ, 2007, 85(9): 719-726.
- 2. Lu W, Duan X, Cen Y. Overview in Epidemiology on Cervical Cancer. Inner Mongolia Med, 2007, 39(8): 967-970.
- 3. Sanjose SD, Quint WG, Alemany L,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11(11): 1048-1056.
- 4. Zhu FC, Chen W, Hu YM,et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer, 2014, 135(11): 2612-2622.
- 5. 人乳头瘤病毒预防性疫苗临床试验有效性评估专家组. 有关人乳头瘤病毒预防性疫苗临床试验有效性评估的专家共识. 中华肿瘤杂志, 2013, 35(7): 552-554.
- 6. Levin CE, Sellors J, Shi JF,et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 2010, 127(6): 1404-1411.
- 7. 唐晓, 乔友林, 李国荣, 等. Markov 模型在DALY 计算中的应用. 中国卫生统计, 2012, 29(2): 296-298.
- 8. Simonella L, Howard K, Canfell K. A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes, 2014, 7(1): 899.
- 9. 慈璞娲, 赵方辉, 王临虹, 等. 宫颈上皮内瘤变自然史转移概率的研究. 中国肿瘤, 2011, 20(9): 694-698.
- 10. 陈蕊. 利用 Markov 模型对宫颈癌筛查方案的卫生经济学评价研究与应用. 华南理工大学, 2015.
